Werewolf Therapeutics Q2 EPS $(3.82) Down From $0.22 YoY
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(3.82) per share. This is a 1836.36 percent decrease over earnings of $0.22 per share from the same period last year.
62 Biggest Movers From Yesterday
Gainers
NeuroMetrix, Inc. (NASDAQ: NURO) shares surged 208% to settle at $10.04 on Tuesday as the company said it received FDA breakthrough device designation for the treatment of fibromyalgia with its wearable neurostimulation technology.
61 Biggest Movers From Yesterday
Gainers
BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.
60 Biggest Movers From Yesterday
Gainers
Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related logistics assets.
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
The Past Week’s Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
Once again, some insiders have taken advantage of initial public offerings.
A couple of chief executive officers were among the insiders buying shares this past week.
Werewolf Therapeutics Priced 7.5M Share IPO @$16/Share
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share.